Docetaxel in Treating Children With Recurrent Solid Tumors
Phase II trial to study the effectiveness of docetaxel in treating children with recurrent solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Brain and Central Nervous System Tumors
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURRENT SOLID TUMORS|
|Study Start Date:||January 1997|
|Primary Completion Date:||December 2004 (Final data collection date for primary outcome measure)|
Experimental: Arm I
All patients receive docetaxel with G-CSF every 21 days for up to 12 courses.
|Biological: filgrastim Drug: docetaxel|
I. Determine the response rate to docetaxel in children with recurrent sarcomas, neuroblastomas, or brain tumors.
II. Describe the toxic effects of docetaxel in these patients.
All patients receive docetaxel with G-CSF every 21 days for up to 12 courses. Patients are followed for survival.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002825
Show 36 Study Locations
|Study Chair:||Theodore Zwerdling, MD||University of California, Davis|